# Xgeva (denosumab) is crucial in preventing SREs in patients with bone metastases and treating high-risk osteoporosis.

*biotech · news · 2026-05-07 · GlobeNewswire*

## Key points

- In March 2024, the MHRA approved a high-concentration Xgeva prefilled syringe formulation.
- Alvotech and Dr. Reddy's Laboratories partnered in May 2024 for a denosumab biosimilar.
- Estimates predict about 510 new annual cases of bone sarcoma in the UK by 2038-2040.
- Asia-Pacific is projected as the fastest-growing region in the Xgeva market.

**Companies:** Amgen Inc.
**Countries:** USA, Canada, UK, France, Germany, Australia, India, China, South Korea, Japan

[Read the full story on GlobeNewswire](https://www.globenewswire.com/news-release/2026/05/07/3290169/28124/en/xgeva-amgen-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-forecasts-2020-2025-2025-2030f-2035f.html)

---

Canonical: https://newsio.io/n/6cd9c436-40ff-48f9-b975-7f5e6c981981/xgeva-denosumab-is-crucial-in-preventing-sres-in-patients-with-bone-metastases-a
Summarized by Newsio from GlobeNewswire. https://newsio.io/how-it-works